Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RESEARCH TOOLSreports
Holding RARE?
Track your performance easily
RARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$37.02 - $60.37
Previous Close$44.75
Volume818.89K
Average Volume (3M)722.07K
Market Cap
$4.13B
Enterprise Value$3.52B
Total Cash (Recent Filing)$621.61M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Feb 13, 2025EPS Estimate
-$1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.46
Shares Outstanding92,344,268
10 Day Avg. Volume1,202,353
30 Day Avg. Volume722,068
Standard Deviation0.14
R-Squared0.05
Alpha0.00652
Financial Highlights & Ratios
Price to Book (P/B)11.90
Price to Sales (P/S)8.42
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.73
Enterprise Value/Gross Profit9.04
Enterprise Value/Ebitda-9.06
Forecast
1Y Price Target
$92.53Price Target Upside106.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Ultragenyx Pharmaceutical News
PremiumCompany Announcements
Ultragenyx Reports Strong Q3 Growth and MilestonesBulls Say, Bears Say
Bulls Say
Financial PerformanceStrong 2Q24 revenues outpaced expectations and led management to raise top-line 2024 guidance.
Market PotentialSetrusumab could represent a significant revenue opportunity in the US, given the prevalence of osteogenesis imperfecta and the lack of approved branded treatments.
Product DevelopmentThe setrusumab program in osteogenesis imperfecta is viewed as a potential near-term blockbuster product.
Bears Say
Program FocusUltragenyx provided an update on the Cyprus2+ study for UX701 in Wilson disease, with the company opting to add a higher dose cohort before moving to Stage 2; this program is not viewed as a core focus for the stock.
Study DelayThe addition of a higher dose cohort for the UX701 study is expected to delay the study by at least 6 months.
Timeline ExtensionFor Wilson's disease treatment, additional optimization is needed, which is estimated to push the timeline out by about a year.
---
Ownership Overview
3.98% Insiders
29.88% Mutual Funds
36.83% Other Institutional Investors
14.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $37.02 and its highest was $60.37 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Currently, no data Available
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Feb 13, 2025 which is in 82 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Nov 05, 2024. The company reported -$1.4 earnings per share for the quarter, beating the consensus estimate of -$1.484 by $0.084.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -$1.35.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 92,344,270 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$1.4 in its last earnings report, beating expectations of -$1.484. Following the earnings report the stock price went down -3.181%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Sands Capital Management LLC. It holds Ultragenyx Pharmaceutical’s shares valued at 297M.
---
Ultragenyx Pharmaceutical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.53 (106.77% Upside)
$92.53 (106.77% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 100%
Sector Average 73%
Sector Average 73%
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.6%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.50%
12-Months-Change
Fundamentals
Return on Equity
-295.34%
Trailing 12-Months
Asset Growth
24.25%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
---
RARE Company Deck
---
RARE Earnings Call
Q3 2024
0:00 / 0:00
---
RARE Stock 12 Month Forecast
Average Price Target
$92.53
▲(106.77% Upside)
Technical Analysis
Allogene Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering RARE
1 Year
1 Year Success Rate
12/18 ratings generated profit
1 Year Average Return
+3.67%
reiterated a buy rating 5 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +3.67% per trade.
---